Search Results

Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We begin with a commentary from Eleni Armeni and Ashley Grossman on seliciclib, a potential new treatment for patients with Cushing’s […]

Cushing’s disease (CD) is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, or rarely carcinoma, and is considered a highly morbid endocrine disorder with few medical options.1,2 Although transsphenoidal pituitary surgery (TSS) is the mainstay of treatment for this disease, up to one-third of the patients eventually relapse and are required to be treated with a […]

Despite the increasing body of knowledge of treatment strategies for diabetes, many patients with type 2 diabetes mellitus (T2DM) are still in a persistent state of poor glycaemia.1,2 In clinical practice, achieving optimal glycaemic targets is challenging; the reasons are complex, as both patient- and healthcare provider (HCP)-related factors can play a significant role.3,4 When lifestyle […]

Acromegaly is a chronic disease caused by an excess of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).1,2 Besides facial and acral changes, systemic complications lead to decreased quality of life and survival rates.3 The primary goal of acromegaly treatment is to normalize biochemical parameters, which significantly reduces the risks of complications and comorbidities associated with […]

Osilodrostat, a novel potent oral steroidogenesis inhibitor, has recently been approved for the treatment of adult patients with endogenous Cushing’s syndrome (CS), and Cushing’s disease (CD) not cured by pituitary surgery or in whom pituitary surgery is not an option. Osilodrostat acts by inhibiting the adrenal enzymes 11-beta-hydroxylase and aldosterone synthase, and by inducing the […]

The incidence of youth-onset type 2 diabetes (T2D) is increasing.1,2 Growing evidence has demonstrated that youth-onset T2D is rapidly progressive, with earlier onset of life-limiting complications compared with adult-onset T2D.3,4 Initiation of effective treatment that can restore beta cell function is critical. Until 2019, metformin and insulin were the only medications approved by the United States […]

Insulin remains an important diabetes treatment, with 150–200 million people worldwide requiring insulin therapy.1 While insulin is vital for managing type 1 diabetes, basal insulin is typically recommended for type 2 diabetes when non-insulin therapies are not enough to achieve glycaemic targets.2 Several barriers related to basal insulin therapy for type 2 diabetes contribute to non-achievement of glycaemic targets, including delay of insulin initiation or […]

Chylomicronaemia refers to the pathological presence of large, circulating, intestinally derived chylomicrons.1 Clinical features of chylomicronaemia syndrome include lipaemic plasma, lipaemia retinalis, eruptive xanthomas, hepatosplenomegaly, neurological symptoms such as mental fog and mood changes and, most importantly, increased risk of acute pancreatitis.1,2 When smaller atherogenic triglyceride (TG)-rich lipoproteins are concomitantly elevated, the risk of myocardial infarction […]